Eli Lilly and Company
LLY
$839.96
$105.0614.30%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 102.08% | 67.79% | 13.00% | 7.94% | -16.08% |
| Total Depreciation and Amortization | 15.67% | 10.23% | 10.04% | 8.04% | 0.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 250.08% | 455.31% | 194.23% | 274.34% | 391.70% |
| Change in Net Operating Assets | -76.27% | -795.66% | -865.46% | -2,615.33% | -381,775.00% |
| Cash from Operations | 107.96% | -2.94% | -27.75% | -45.90% | -44.10% |
| Capital Expenditure | -46.70% | -60.98% | -68.42% | -74.53% | -85.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 9.25% | -508.80% | -508.80% | -219.16% | -219.16% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.87% | -87.13% | -1,509.59% | -204.66% | -68.26% |
| Cash from Investing | -30.04% | -99.26% | -207.91% | -123.82% | -90.08% |
| Total Debt Issued | 31.99% | 320.01% | 233.72% | 124.82% | 477.43% |
| Total Debt Repaid | -- | -- | 35.19% | -57.88% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -233.33% | 40.52% | 100.00% | 100.00% | 50.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.02% | -15.11% | -15.11% | -15.10% | -15.09% |
| Other Financing Activities | -46.45% | -50.33% | -38.26% | -44.33% | -8.45% |
| Cash from Financing | -64.81% | 520.01% | 277.17% | 231.00% | 164.65% |
| Foreign Exchange rate Adjustments | -275.98% | 393.70% | 140.39% | 161.39% | 200.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.15% | 517.67% | 638.97% | -199.91% | 142.91% |